Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082127 | 0.87 | BACE1 (0.57) | BACE1BACE2 | |
| SCHEMBL10194396 | 0.87 | BACE1 (0.74) | BACE1BACE2 | |
| SCHEMBL4087191 | 0.87 | BACE1 (0.56) | BACE1BACE2 | |
| SCHEMBL4077187 | 0.86 | MAPK1 (0.59) | BACE1BACE2 | |
| SCHEMBL4084959 | 0.83 | BACE1 (0.62) | BACE1BACE2 | |
| SCHEMBL4086977 | 0.83 | BACE1 (0.61) | BACE1BACE2 | |
| SCHEMBL4087171 | 0.82 | BACE1 (0.67) | BACE1BACE2 | |
| SCHEMBL4075990 | 0.81 | BACE1 (0.68) | BACE1BACE2 | |
| SCHEMBL4084941 | 0.80 | BACE1 (0.67) | BACE1BACE2 | |
| SCHEMBL4085326 | 0.80 | BACE1 (0.67) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884062-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8884062-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140073815-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-20140073815-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8507479-B2 | — | — | 2013-08-13 | — | — | US | disclosed |
| US-8507479-B2 | — | — | 2013-08-13 | — | — | US | disclosed |
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8168630-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8168630-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | BACE1 6/4885BACE2 14/4885 |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | BACE1 5/4885BACE2 14/4885 |
| US-20140073815-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | BACE1 6/4885BACE2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.